The performance of companies tied to the drug's legacy presents a intricate investment scenario . While the initial boom generated substantial gains, generic competition have significantly impacted sales . Investing in related pharmaceutical firms now requires a careful assessment of patent rights , evolving medical changes, and the possibility for